EyeGate Pharmaceuticals Announces a $10 Million Public Offering
Monday, June 12, 2017 12:23 AM
WALTHAM, Mass.—EyeGate Pharmaceuticals Inc.
(NASDAQ:EYEG), a specialty pharmaceutical company that focuses on developing and commercializing treatments for diseases and disorders of the eye, reported last week that it has set the pricing of a public stock offering that is expected to raise gross proceeds of $10 million.
EyeGate said it will use the net proceeds of the offering to support its operations, including for clinical trials, for working capital and for other general corporate purposes.
The offering was priced at $1.50 per share of common stock (or common stock equivalent), with each share of common stock (or common stock equivalent) sold with one five-year warrant to purchase one share of common stock, at an exercise price of $1.50 per share, according to the announcement.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as exclusive placement agent for the offering, according to EyeGate. It is expected to close on or about June 14, subject to certain customary closing conditions, EyeGate reported.